Contact
searchSearch
HMP Global
CIO 2020

New Data: LEGACY Study & IRs During COVID-19

Osman Ahmed, MD
12/14/2020

Dr Osman Ahmed

Osman Ahmed, MD, FCIRSE, Assistant Professor of Vascular and Interventional Radiology at University of Chicago Medicine in Chicago, Illinois, discusses the recently published LEGACY Study, which confirmed Boston Scientific’s TheraSphere™ as a neoadjuvant or standalone therapy in treating hepatocellular carcinoma. In addition, Dr Ahmed offers his thoughts on interesting new data that demonstrate the strength of Interventional Radiology amidst COVID in comparison with other specialties.

Related Content

Abstracts
Symposium on Clinical Interventional Oncology 2026 Abstracts
11/04/2026
Vascular Disease Management is pleased to publish the accepted abstracts from the upcoming Symposium on Clinical Interventional Oncology (CIO).
Vascular Disease Management is pleased to publish the accepted abstracts from the upcoming Symposium on Clinical Interventional Oncology (CIO).
Vascular Disease Management is...
11/04/2026
Vascular Disease Management
Deep Learning
Deep Learning Model Predicts Hepatocellular Carcinoma Progression Following Transarterial Chemoembolization
10/09/2026
Laura Simson, MA
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining...
10/09/2026
Vascular Disease Management
TARE vs TACE
TARE Improves Outcomes vs TACE for Large Unresectable HCC
09/14/2026
Laura Simson, MA
A 2026 retrospective study of patients with solitary unresectable hepatocellular carcinoma found that transarterial radioembolization was associated with longer adjusted overall survival and local progression-free survival than transarterial...
A 2026 retrospective study of patients with solitary unresectable hepatocellular carcinoma found that transarterial radioembolization was associated with longer adjusted overall survival and local progression-free survival than transarterial...
A 2026 retrospective study of...
09/14/2026
Vascular Disease Management
Case Report
Off-Label Flow Diverter Stent as a Salvage Technique for Early Post-Liver Transplant Hepatic Arterial Occlusion: A Novel Technique
07/15/2026
Santhosh Babu K.B, MBBS, MD, FNVIR; Ashish Goel, DM, MD; Shyamkumar Nidugala Keshava, MBBS, DMRD, DNB, FRCR, FRANZCR
The authors describe a case report where an off-label technique was performed using a flow diverter stent.
The authors describe a case report where an off-label technique was performed using a flow diverter stent.
The authors describe a case...
07/15/2026
Vascular Disease Management

About Us

Vascular Disease Management™ (VDM), the official media partner of the International Symposium on Endovascular Therapy (ISET) and the Amputation Prevention Symposium (AMP), is a monthly peer-reviewed online journal that educates readers on the latest advancements in endovascular treatment strategies. 

Learn more about ISET and AMP and register for the events here:

ISET logo

AMP logo

Subscribe Now!

Vascular Disease Management Newsletter

News

LAA Occluders
Late-Breaking One-Year Data Show Abbott's Next-Generation Amulet 360™ Device Continues to Demonstrate High Rates of Left Atrial Appendage Closure and Low Incidence of Stroke
11/03/2026
Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions;data show the device achieved high closure rates of...
Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions;data show the device achieved high closure rates of...
Late-breaking one-year...
11/03/2026
Vascular Disease Management
Intravascular Lithotripsy
Abbott's TECTONIC Clinical Trial Demonstrates Strong 30-day Outcomes and High Procedural Success for Its Investigational SonicForce™ Coronary Intravascular Lithotripsy System
11/03/2026
11/03/2026
Vascular Disease Management
Stroke Clinical Trials
Could A Drug for Leg Cramps Prevent a Second, Deadlier Stroke? 
10/30/2026
The trial is funded by the National Institute of Neurological Disorders and Stroke (NINDS) and is open to patients diagnosed within the last six months with an ischemic stroke or high-risk transient ischemic attack (TIA).
The trial is funded by the National Institute of Neurological Disorders and Stroke (NINDS) and is open to patients diagnosed within the last six months with an ischemic stroke or high-risk transient ischemic attack (TIA).
The trial is funded by the...
10/30/2026
Cath Lab Digest
Radiation Safety
Rampart Launches Vanguard™ at TCT 2026, Extending Total-Body Radiation Protection to Interventional Imagers
10/29/2026
Purpose-built head-of-table solution advances the Shed the Lead® movement as new multisociety guidance calls for enhanced radiation protection.
Purpose-built head-of-table solution advances the Shed the Lead® movement as new multisociety guidance calls for enhanced radiation protection.
Purpose-built head-of-table...
10/29/2026
Vascular Disease Management
Peripheral Arterial Bleeds
Instylla's Embrace® Hydrogel Embolic System Receives FDA Approval for Peripheral Arterial Bleeds
10/29/2026
10/29/2026
Vascular Disease Management
Large-Bore Closure
Haemonetics Announces FDA Approval of PerQseal Elite Vascular Closure System
10/27/2026
The PerQseal Elite system provides sutureless, large-bore vascular closure following structural heart and endovascular procedures performed with 14 – 22F sheaths. Its fully bioabsorbable patch seals arteriotomies up to 26F from within the...
The PerQseal Elite system provides sutureless, large-bore vascular closure following structural heart and endovascular procedures performed with 14 – 22F sheaths. Its fully bioabsorbable patch seals arteriotomies up to 26F from within the...
The PerQseal Elite system...
10/27/2026
Cath Lab Digest
FDA Approvals
Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
10/20/2026
ALAMEDA, Calif. -- Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™)...
ALAMEDA, Calif. -- Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™)...
ALAMEDA, Calif. -- Penumbra,...
10/20/2026
Cath Lab Digest
Vertex PE System (Jupiter Endovascular)
Pulmonary Embolism
Jupiter Endovascular Announces Publication of SPIRARE II Pivotal Trial Results Showing Vertex Thrombectomy System Normalized Hemodynamics in 50% of Pulmonary Embolism Patients
10/19/2026
The Vertex system leverages the company’s proprietary Transforming Fixation (TFX) platform technology, a single catheter designed to navigate flexibly through the right heart and stabilize on-demand in the pulmonary arteries for precise,...
The Vertex system leverages the company’s proprietary Transforming Fixation (TFX) platform technology, a single catheter designed to navigate flexibly through the right heart and stabilize on-demand in the pulmonary arteries for precise,...
The Vertex system leverages the...
10/19/2026
Cath Lab Digest
Endovascular Aortic Repair
FDA Approves GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis for Expanded use in FEVAR and BEVAR
10/15/2026
10/15/2026
Vascular Disease Management
Deep Learning
Deep Learning Model Predicts Hepatocellular Carcinoma Progression Following Transarterial Chemoembolization
10/09/2026
Laura Simson, MA
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining...
10/09/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use